Cerus Corporation ((CERS)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: Cerus Corporation is conducting an open-label, controlled Phase 2 study titled Challenge Transfusion of INTERCEPT Pathogen Reduced Red Blood Cells (RBCs) in Subjects With or Without Pre-existing Antibodies to INTERCEPT RBCs. The study aims to assess whether transfusing INTERCEPT RBCs into patients with pre-existing antibodies will increase antibody titers, indicating a secondary immune response, and whether these responses are linked to adverse events, increased RBC clearance, or hemolysis. The study also seeks to evaluate the recovery and survival of INTERCEPT RBCs in patients with various diseases.
Intervention/Treatment: The study tests the INTERCEPT RBCs, a device used for transfusion of fresh allogeneic red blood cells, aiming to reduce pathogens and improve transfusion safety.
Study Design: This interventional study is non-randomized with a parallel assignment model. It involves no masking and primarily focuses on screening. Participants are divided into two groups: those with antibodies to INTERCEPT RBCs and those without.
Study Timeline: The study is not yet recruiting as of the last update on August 26, 2025. The study was first submitted on the same date. Key dates for primary and estimated completion are yet to be determined.
Market Implications: The study’s progress could influence Cerus Corporation’s stock performance and investor sentiment, especially if the results demonstrate improved safety and efficacy of INTERCEPT RBCs. This could position Cerus favorably against competitors in the transfusion medicine market.
The study is ongoing, with further details available on the ClinicalTrials portal.